fy faster. The cyclostomes can't rebound under the weight of their more diverse competitor, but neither do they collapse, thanks to their lower rate of extinction, a handy attribute of uncertain origin. This match between model and fossil record, plus the obvious competition recorded in bryozoan overgrowths, is consistent with "competition as a significant influence on diversity histories" of bryozoans, the group concludes.

The study represents "the most persuasive analysis yet of an apparent competitive displacement" of one clade by another, says paleontologist Alan Cheetham of the Smithsonian Institution's National Museum of Natural History in Washington, D.C. However, "they don't claim they've proven what happened." Indeed, "the model is a description rather than an explanation," notes Bambach. Although competition looks like a promising explanation, he says, others are possible. Taylor agrees, offering the possibility that a new type of cheilostome larval stage, rather than overgrowth of the competition, may have given cheilostomes an edge.

To strengthen the case for competition in evolution, paleontologists agree, researchers must learn more about all the ways bryozoa compete today. In the meantime, although Sepkoski's "death was hard for a lot of us," says paleontologist Arnold Miller of the University of Cincinnati, "he left us some things to think about."

-RICHARD A. KERR

COLLABORATIVE RESEARCH

Plans for Mars Unite Cancer, Space Agencies

Cancer research and sending humans to Mars may seem light-years apart, but technological advances have put them on the same flight path. Last week NASA and the National Cancer Institute (NCI) announced that each intends to spend \$10 million a year for the next 5 years in a coordinated effort to develop devices that could both speed detection of cancer on Earth and keep astronauts healthy during long sojourns from home.

To drum up enthusiasm for the idea, NASA Administrator Dan Goldin and NCI director Richard Klausner brought together two dozen molecular biologists, geneticists, pharmacologists, and chemists to discuss how nanotechnology and bioengineering can revolutionize health care on Earth and in space. "We're bringing medicine out of the hospital," says David Baltimore, president of the California Institute of Technology in Pasadena and chair of the NASA-NCI working group on biomolecular systems and technology. "It's a terrific opportunity." However, he warned that inter-

FRGENE

C

agency efforts are "the most cumbersome activity on Earth."


Goldin and Klausner hatched the idea for a collaboration 3 years ago at a dinner party hosted by Bruce Alberts, president of the National Academy of Sciences, and shepherded it through their agencies. Last year, as part of a pilot program in unconventional innovations, NCI awarded five grants, worth \$11 million, for technologies to detect and diagnose cancer that involved nanoscience, near-infrared optical techniques, and new polymers. One went to a scientist at NASA's Ames Research Center in Mountain View, California. Last June, a joint NASA-NCI meeting at Ames drew 150 investigators to examine advances in sensors to detect the signature of specific biomolecules.

Under the new agreement, the agencies will disburse grants separately but be free to supplement one another's projects. Klausner gains access to the space agency's expertise in building small and lightweight hardware, while Goldin bolsters the scientific credibility of NASA's human space flight program and strengthens ties to the burgeoning biological community. Astronauts bound for Mars may be in space for more than 4 years, bombarded by dangerous radiation and facing situations where even minor accidentssuch as a rip in a space suit-could prove disastrous. Combating such threats may call for machines that can screen for genetic damage at a very early stage, robotic sensors injected into astronauts that continuously monitor their health, and a self-repairing space suit. Such innovations have revolutionary implications for improving health care on Earth, adds Klausner.

Of course, the health issue could be moot if humans don't take any long trips in space. "Why not learn to build robots to do business on Mars?" asked Stanford geneticist David Botstein at a 13 April public panel discussing the new collaboration. Even Baltimore noted



Tiny helpers. Nanoscale sensors would collect health data during long trips in space.



Science in the Parks Canadian biologists are welcoming a new plan for making ecological science the foundation for managing the country's 39 national parks. But they have mixed feelings about another proposal to protect endangered species.

Two years ago, in the wake of public debate over proposed development in the parks, the Minister of Canadian Heritage appointed a scientific committee to examine park management. Last month, the panel recommended making "ecological



making "ecological integrity"—preserving intact assemblages of native organisms—managers' "first priority." The panel's report also calls for adding C\$328 million to the Parks Canada budget over 5 years and hiring more staff to supplement the present team of 51 scientists. The ambitious proposal parallels a similar effort in U.S. national parks (*Science*, 7 April, p. 34) and has won support from politicians. "I think the political mood is there [to implement the plan]," says panel member Tom Nudds, an ecologist at the University of Guelph, Ontario.

But many biologists are less enthusiastic about a plan to protect threatened species. Introduced by the government last week, the Species at Risk Act would impose stiff penalties for killing protected plants and animals. Critics are unhappy that the bill leaves final listing decisions to the Cabinet rather than scientists and doesn't make protecting habitat mandatory. But after 7 years of debate, even some skeptics are hoping the bill will pass this year, warts and all, so Canada will finally have an endangered species law.

Metric Mandate Complaining that NASA's approach to projects is "faster, cheaper, worse," Representative Vern Ehlers (R–MI) says he is drafting legislation requiring government contractors, scientists, and engineers to use exclusively metric measures. That's in response to the 1999 failure of the Mars Climate Orbiter due to a mix-up between English and metric units (*Science*, 7 April, p. 32). "He wants to send a clear message ... that we won't tolerate mistakes like this again," says an aide.

Contributors: Govert Schilling, Jeffrey Mervis, Jocelyn Kaiser, Andrew Lawler

NEWS OF THE WEEK

that the "radiation problem is very severe" and predicted it will be hard to overcome. But Goldin says both robots and humans ultimately will be needed for Mars exploration.

The working group has been asked to set near- and long-term goals for the kinds of technology and research infrastructure needed. A self-described "cheerleader" for the program, Baltimore says that the venture "is a real opportunity for thinking in novel ways about programs that cut across two agencies. ... Interdisciplinary science is on everyone's tongue. Today, it's a reality."

-ANDREW LAWLER

Are Placebo-Controlled Drug Trials Ethical?

HOUSTON—The psychiatric research community is increasingly polarized by a seem-

ingly simple question: Is it ethical to use placebos in drug trials? Specifically, can you give some of your patients a dummy pill, if it means suspending their regular medication and possibly worsening their symptoms? Critics argue that doing so makes patients suffer unnecessarily and may drive some to suicide. But the Food and Drug Administration (FDA) has insisted that placebo-controlled trials are the only scientifically sound way to test the efficacy of most psychiatric

drugs. Drug companies say they have no choice but to comply, and most researchers have gone along—some of them reluctantly.

Now, the FDA has two large metaanalyses to defend its policy. Both show that being in a placebo group does not increase the risk of suicide. But those studies—the most definitive to date—seem unlikely to quell the controversy. At a meeting* earlier this month where one of the studies was presented, critics lashed out again at placebocontrolled trials, calling them "unethical" and "immoral." Karin Michels, a clinical epidemiologist from Harvard University, asked: "If the patient was your son or your mother, would you withdraw active treatment from them for the sake of science?"

Instead of using fake pills, critics argue that new psychiatric drugs should be compared to one of the many drugs already on the market. Nobody would even consider using placebos for such treatable diseases as cancer and AIDS, Michels pointed out, adding that the practice violates the Declaration of Helsinki. Worse still, some psychiatric patients sign up for such trials without fully understanding what they're getting into, said Harold Vanderpool of the University of Texas (UT) Medical Branch in Galveston. For these reasons, Institutional Review Boards (IRBs), the panels at universities and hospitals that scrutinize trials for human risks, are increasingly loath to approve the use of placebos in psychiatric trials, says Paula Knudson, who administers an IRB at UT Houston.

But FDA maintains that psychiatric drugs—and some others, such as antihypertensives—are a special case because their effects are notoriously hard to prove. It's common in these trials for 30% to 50% of the patients in the placebo group to improve, thanks to a phenomenon called the placebo effect, while those on the real drug improve

just a bit more. Indeed, even already-approved drugs regularly fail to beat placebos in later trials. If all FDA demanded was that a new drug perform as well as an old one, it would have no way of knowing how much of that improvement was caused by the placebo effect, officials say.

Because the placebo effect is so fickle, and nobody knows how to reduce it, FDA usually recommends that psychiatric drugs be tested in threearmed trials, in which a pared to a placebo and an ex-

new drug is compared to a placebo and an existing treatment. If both drugs fail to beat the placebo, the whole trial is written off as a failure. Some people may be worse off from getting a placebo instead of an approved treatment, admits Thomas Laughren, team leader of FDA's Psychiatric Drug Products Group, but that's an acceptable risk as long as patients' lives are not at stake.

Laughren believes they are not. He and his colleagues conducted a meta-analysis of every recent trial submitted to FDA to win approval for eight new antidepressants (including blockbusters such as Prozac and Zoloft) and four antipsychotic drugs. More than 42,000 patients took part in these trials. In the antidepressant trials, 0.02% of the patients in the placebo group committed suicide during the trial, compared with 0.10% in the groups that received an older drug. Laughren cautioned that those results must still be corrected for the amount of time patients spent in the trial, but he was confident that won't significantly alter the outcome. Trials with schizophrenic patients showed similar results. And the outcomes also match those from a smaller study led by psychiatrist Arif Khan from the Northwest Clinical Research Center in Bellevue, Washington, who looked at FDA data from seven antidepressant trials that together enrolled almost 20,000 people. The study, published in the April *Archives of General Psychiatry*, also failed to see an increased suicide risk.

But the critics are unimpressed. The Khan paper, for instance, is accompanied by six commentaries-three of them arguing that the study doesn't justify the use of placebo controls. Suicide is just one risk psychiatric patients face, says Michels. "Shouldn't we also think of the quality of life of the people we're withholding the active treatment from?" she asks. And Vera Hassner Sharav, president and founder of a New York City lobby group called Citizens for Responsible Care and Research, adds that suicide rates in all trial groups may have been increased; simply enrolling in a study that includes a placebo arm causes great stress and anxiety in some patients, she says. Michels and Hassner Sharav argue that trials that compare two active drugs could produce statistically relevant outcomes if they had more patients, time, and money.

Despite the arguments, participants at the Houston meeting did find common ground. Only patients fully capable of making a sound decision should be enrolled in trials, and they should be informed as fully as possible. Researchers can also reduce risks by screening out patients likely to harm themselves or others and by making sure there's a friend or family member on standby. IRBs should be especially vigilant, says Knudson. Her own panel has sometimes required that severely depressed or psychotic patients be hospitalized for the first 3 weeks of a trial to make sure they're okay. Pharmaceutical companies and researchers don't necessarily like these restrictions, she concedes, but they do provide a safeguard.

-MARTIN ENSERINK

Revealing a Dinosaur's Heart of Stone

In the fall of 1998, Andrew Kuzmitz, a physician in Ashland, Oregon, invited seven cardiologists to a local hospital to view a computerized tomography (CT) scan. The experts all agreed on what they were seeing: two large, oval chambers or ventricles, divided by a septum. "Every one of them said, 'It's a heart,'" says Kuzmitz. But this was no ordinary heart: It belonged to a 66-million-year-old dinosaur. "As soon as I put the scan

"If the patient was your son or your mother, would you withdraw active treatment?"

-Karin Michels

^{*} Placebo in mental health research: Science, ethics and the law, UT Houston, 7 to 8 April.